Updated:
Edgewise Therapeutics
Kevin Koch's Edgewise Therapeutics targets muscle disease at the sarcomere level — a precision biotech with a Phase 3 clinical candidate.
Edgewise Therapeutics
Edgewise Therapeutics was founded in 2017 by Kevin Koch and Alan Russell, emerging from the University of Colorado Boulder's muscle-biology research community. Koch, who previously co-founded Array BioPharma and held senior R&D roles at Pfizer, saw a mechanistic gap: most muscle-wasting treatments chased strength, but none directly prevented the contraction-induced microdamage that drives disease progression. The firm's originating insight is that stabilizing fast skeletal muscle myosin could keep muscle fibers intact, not just temporarily stronger. Edgewise's entire pipeline is built on its skeletal and cardiac muscle precision platform. The lead candidate, sevasemten (EDG-5506), is a fast myosin modulator in Phase 3 trials for Becker muscular dystrophy and Phase 2 for Duchenne muscular dystrophy (per the firm's public disclosures, 2025). The company is also advancing EDG-7500, a cardiac myosin modulator, into clinical trials for hypertrophic cardiomyopathy. The asset mix is narrowly focused on rare neuromuscular and cardiac conditions — no oncology, no metabolic spinoffs, no platform licensing — just myosin modulation across two organs. Geographically, Edgewise is headquartered in Boulder, Colorado, with clinical operations concentrated in the United States and select European trial sites. Edgewise raised over $200 million in private financing from backers including Orbimed, Novo Holdings, and RA Capital before executing a Nasdaq IPO in March 2021 that brought in approximately $200 million more (per SEC filings). As of early 2026, the company reported a cash runway extending into 2028, supporting ongoing pivotal trials. Alongside its clinical ambitions, the firm has maintained a lean corporate structure without sprawling divisions or multiple subsidiaries. March 2025: Reported positive 24-month data from its Phase 2 CANYON trial of sevasemten in Becker muscular dystrophy, demonstrating sustained function in muscle assessments (per the firm, March 2025). The structural differentiator for Edgewise is its platform-in-product architecture. Nearly all the company's value rests on sevasemten, but the asset was built from a mechanistically distinct screening engine that systematically selects myosin modulators rather than borrowing molecules designed for other targets. This combination of extreme clinical concentration and novel discovery chemistry gives it the risk profile of a late-stage biotech but the IP posture of a platform company. If sevasemten reads out in Phase 3, the engine instantly has clear economics in multiple indications — and the firm has no legacy distractions to manage alongside it.
General information
Firm type
Asset Manager
Year founded
2017
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boulder
Corporate office
Boulder, CO, United States
Principals
Kevin Koch
President and Chief Executive Officer
Alan Russell
Chief Scientific Officer
R. Michael Carruthers
Chief Financial Officer
Sector focus
Frequently asked questions
What is the lead therapeutic mechanism at Edgewise Therapeutics?
Edgewise targets fast skeletal muscle myosin in its lead program and cardiac myosin in its pipeline. The logic is that stabilizing sarcomere function prevents contraction-induced injury, which it views as the root cause of muscle wasting in Becker and Duchenne muscular dystrophy rather than simply downstream inflammation or fibrosis. This mechanism-first approach emerged from the founders' research at the University of Colorado.
Who founded Edgewise and what experience did they bring?
Kevin Koch, President and CEO, co-founded Array BioPharma and led Biofrequency Research before Edgewise, after an earlier career as a medicinal chemist at Pfizer. Alan Russell, Chief Scientific Officer, brought deep muscle-biology expertise from his academic work. The original IP was licensed from the University of Colorado, where the team identified the myosin-stabilization mechanism that underpins the company's pipeline.
Is Edgewise a single-asset company or a platform?
Practically, nearly all value rests on sevasemten, the fast-muscle myosin modulator in late-stage trials. But the discovery engine is a platform — systematic myosin screening across skeletal and cardiac isoforms. The company already has a second compound, EDG-7500, in the clinic for hypertrophic cardiomyopathy, which validates the platform's translatability across muscle types.
Which investors backed Edgewise before its IPO?
Edgewise's private syndicate included major life-science specialists such as OrbiMed, Novo Holdings, RA Capital, and Perceptive Advisors. These investors came in across several rounds totaling over $200 million and maintained significant ownership through the 2021 IPO. Their continued involvement signals institutional conviction in the myosin-modulation thesis.
What remains the biggest regulatory risk for Edgewise?
The pivotal Phase 3 trial for sevasemten in Becker muscular dystrophy is the make-or-break event. Becker is a rare disease with no approved therapies — making the regulatory path a two-edged sword: clear unmet-need advantage but limited precedent on endpoints. The drug also needs to demonstrate durable function without compromising cardiac safety, a known complexity in fast-myosin modulation.
Does Edgewise have any commercial partnerships or licensing deals?
Edgewise has not announced any major co-development or commercialization partnerships. As of its latest public filings, the company retains full worldwide rights to sevasemten and EDG-7500. This clean ownership structure means the firm faces the full cost and risk of pivotal execution but would capture 100% of the economics on approval.
How is Edgewise funded through its current clinical trials?
The company ended its most recently reported quarter with a cash runway extending into 2028, which covers the expected readout period for its pivotal trials. Edgewise has used follow-on equity offerings and its IPO proceeds to fund operations, rather than project-financing debt or royalty deals, which preserves equity value but exposes current shareholders to dilution risk.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: